Microvascular Invasion Is a Better Predictor of Tumor Recurrence and Overall Survival Following Surgical Resection for Hepatocellular Carcinoma Compared to the Milan Criteria

米兰标准 医学 肝细胞癌 肝移植 内科学 比例危险模型 外科 肿瘤科 移植
作者
Kim Lim,Pierce K. H. Chow,John C. Allen,Ghim-Song Chia,Miao-Shan Lim,Peng‐Chung Cheow,Alexander Chung,London Lucien Peng Jin Ooi,Shan Tan
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)]
卷期号:254 (1): 108-113 被引量:408
标识
DOI:10.1097/sla.0b013e31821ad884
摘要

To compare microvascular invasion (McVI) with parameters defined by the Milan criteria in predicting tumor recurrence and overall survival (OS) in patients with surgical resection (SR) for hepatocellular carcinoma (HCC).Although the Milan criteria is discriminatory for selecting patients with good outcomes in liver transplantation and SR for HCC, it neither adequately predict tumor recurrence nor explain differences in survival for patients with good liver function. McVI is a strong indicator of intrahepatic metastasis in HCC, but its relative significance for predicting clinical outcomes compared to the Milan criteria is unclear.Patients undergoing SR with curative intent from January 2000 to March 2009 at the Singapore General Hospital were followed up for long-term outcomes till January 1, 2010. They were stratified first by the Milan criteria and then by the presence of McVI and compared relative to OS.Altogether, 454 of the 515 patients received curative SR. There were stratified into 4 groups (Milan+, McVI-), (Milan+, McVI+), (Milan-, McVI-), and (Milan-, McVI+). All pair-wise comparisons between groups relative to OS were significant except (Milan+, McVI-) (OS, 90%, 73%, and 60% at 1, 3, and 5 years) with (Milan-, McVI-) (OS, 86%, 71%, and 61% at 1, 3, 5 years) and (Milan+, McVI+) with (Milan-, McVI+). Multivariate Cox regression analysis showed that McVI was predictive of OS, after which Milan status did not add additional discriminative information.McVI is a better predictor of tumor recurrence and OS than the Milan criteria after SR for HCC. Assessment of McVI should aid in patient selection for adjuvant treatments to improve outcomes after SR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
7秒前
思源应助科研通管家采纳,获得10
7秒前
科研通AI2S应助科研通管家采纳,获得10
7秒前
orixero应助科研通管家采纳,获得10
7秒前
深情安青应助科研通管家采纳,获得10
7秒前
情怀应助科研通管家采纳,获得10
7秒前
7秒前
科研通AI2S应助科研通管家采纳,获得10
7秒前
7秒前
孙成伟完成签到,获得积分10
8秒前
科研通AI2S应助热心小松鼠采纳,获得30
8秒前
10秒前
13秒前
13秒前
Ava应助秀丽大凄采纳,获得10
14秒前
朝朝发布了新的文献求助10
18秒前
20秒前
jasonwee发布了新的文献求助10
20秒前
shikaly应助称心的绿柏采纳,获得20
22秒前
Rr完成签到,获得积分10
24秒前
HenryPan完成签到,获得积分10
30秒前
qhy发布了新的文献求助10
32秒前
北雨完成签到,获得积分20
32秒前
zho发布了新的文献求助10
35秒前
35秒前
心灵美的大山完成签到,获得积分10
36秒前
37秒前
幸福书琴完成签到 ,获得积分10
40秒前
peipei发布了新的文献求助10
42秒前
44秒前
sherry221完成签到,获得积分10
46秒前
文艺稚晴发布了新的文献求助10
50秒前
tanjuan发布了新的文献求助10
51秒前
53秒前
英俊的铭应助慧敏采纳,获得10
53秒前
獭獭关注了科研通微信公众号
55秒前
海城好人完成签到,获得积分10
58秒前
1分钟前
lin完成签到,获得积分10
1分钟前
科研通AI2S应助Wjc采纳,获得10
1分钟前
高分求助中
求助这个网站里的问题集 1000
Floxuridine; Third Edition 1000
Models of Teaching(The 10th Edition,第10版!)《教学模式》(第10版!) 800
La décision juridictionnelle 800
Rechtsphilosophie und Rechtstheorie 800
Nonlocal Integral Equation Continuum Models: Nonstandard Symmetric Interaction Neighborhoods and Finite Element Discretizations 600
Academic entitlement: Adapting the equity preference questionnaire for a university setting 500
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2873111
求助须知:如何正确求助?哪些是违规求助? 2482078
关于积分的说明 6723186
捐赠科研通 2167318
什么是DOI,文献DOI怎么找? 1151395
版权声明 585724
科研通“疑难数据库(出版商)”最低求助积分说明 565269